Endocrinology (all articles)
RCT | Weekly Somapacitan is noninferior to daily GH in children with GH deficiency.
6 Sep, 2022 | 14:25h | UTC
The Australian obesity management algorithm: a simple tool to guide the management of obesity in primary care.
5 Sep, 2022 | 14:31h | UTC
Nonalcoholic fatty liver disease: review of management for primary care providers.
5 Sep, 2022 | 14:18h | UTC
2022 ACC Expert Consensus | Role of nonstatin therapies for LDL-cholesterol lowering and managing cardiovascular disease risk.
2 Sep, 2022 | 13:17h | UTCNews Release: ACC Issues Guidance to Address New Nonstatin Therapies – American College of Cardiology
Commentary: New on the Scene Nonstatin Drugs: Experts Provide Guidance – TCTMD
Commentary on Twitter
📢 ACC releases Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of ASCVD Risk
Read more: https://t.co/WDOSPgQ1bx #ACCClinicalDoc pic.twitter.com/nt8S2pdBgD
— American College of Cardiology (@ACCinTouch) August 25, 2022
Cohort Studies | Increased consumption of ultra-processed foods linked to increased risk of mortality and cancer.
2 Sep, 2022 | 13:15h | UTCEditorial: The trouble with ultra-processed foods – The BMJ
Commentaries:
Ultraprocessed foods linked to cancer and early death, studies find – CNN
New research gives more reasons to eat less-processed food – The Guardian
RCT | The effect of a liberal approach to glucose control in critically ill patients with type 2 diabetes.
1 Sep, 2022 | 11:37h | UTCThe Effect of a Liberal Approach to Glucose Control in Critically Ill Patients with Type 2 Diabetes: A multicenter, parallel-group, open-label, randomized clinical trial – American Journal of Respiratory and Critical Care Medicine (link to abstract – $ for full-text)
Commentary from the author on Twitter
Excited to share results of the LUCID trial! A liberal approach to blood glucose targets reduced incidence hypoglycemia but did not improve patient-centered outcomes. https://t.co/HO53nzfBQT@MelbourneICU @CRENutrition @BellomoRinaldo @icurah @DogICUma @Eastwoodgm @MACHAustralia
— Alex Poole (@AlexPPoole) May 25, 2022
Guideline | Adult- and late-onset male hypogonadism.
31 Aug, 2022 | 11:36h | UTC
#ESCCongress | Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials.
30 Aug, 2022 | 12:16h | UTCNews Release: Cardiovascular protection from statins greatly outweighs the risk of muscle symptoms – European Society of Cardiology
Commentary: Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration – TCTMD
#ESCCongress – M-A | Patients with heart failure benefit from dapagliflozin regardless of ejection fraction.
30 Aug, 2022 | 12:14h | UTCNews Release: Patients with heart failure benefit from dapagliflozin regardless of ejection fraction – European Society of Cardiology
Related:
Consensus Statement | Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis.
30 Aug, 2022 | 12:10h | UTC
Commentary on Twitter
Lipoprotein(a) in atherosclerotic CV and aortic stenosis – a European Atherosclerosis Society consensus statement https://t.co/Bzzpd3Bx8M
#EHJ #ESCCongress #ESCYoung @escardio @ehj_ed @rladeiraslopes pic.twitter.com/ZcqaPe581K
— European Society of Cardiology Journals (@ESC_Journals) August 29, 2022
#ESCCongress | Study shows long-term Evolocumab appears to be safe in patients with established atherosclerotic cardiovascular disease.
30 Aug, 2022 | 12:12h | UTCNews Release: Long-term evolocumab therapy leads to further reductions in cardiovascular events – European Society of Cardiology
Original Article: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease – New England Journal of Medicine
Commentary on Twitter
#OriginalResearch SimPub #ESCCongress: In this open-label extension of #FOURIER RCT, long-term evolocumab therapy for >8 yrs was associated w/ persistently low rates and greater reduction in MACE compared w/ delayed treatment initiation among patients w… https://t.co/9g97s4MZSt pic.twitter.com/y5uN53gdKo
— Circulation (@CircAHA) August 29, 2022
Case series of acute cholecystitis associated with the use of Glucagon-Like Peptide-1 Receptor agonists reported to the US Food and Drug Administration.
30 Aug, 2022 | 11:59h | UTCAcute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration – JAMA Internal Medicine (free for a limited period)
#ESCCongress – Meta-analysis of randomized trials | SGLT-2 inhibitors in patients with heart failure.
29 Aug, 2022 | 12:35h | UTCSGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials – The Lancet (free registration required)
Commentary on Twitter
Our meta-analysis of SGLT2 inhibitors in HF is now online in @TheLancet showing a
consistent reduction in the risk of CV death and HF hospitalisation in a broad range of 21,947
patients across range of EF and in different care settingshttps://t.co/qnxgayR235 pic.twitter.com/x0RsINoE9y— Kieran Docherty (@Kieranfdocherty) August 27, 2022
#ESCCongress – RCT | Dapagliflozin reduced the risk of worsening heart failure or cardiovascular death in patients with heart failure with mildly reduced or preserved ejection fraction.
29 Aug, 2022 | 12:36h | UTCDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Dapagliflozin benefits patients with mildly reduced and preserved ejection fraction – European Society of Cardiology
Related (#ESCCongress 2021): RCT: SGLT2 inhibition reduced the combined risk of cardiovascular death or hospitalization in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.
Commentary on Twitter
DELIVER: In an RCT involving patients with HF and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of the composite outcome of worsening heart failure or CV death. #ESCCongress https://t.co/0umSDn5HkO pic.twitter.com/nq7zD2Fi2K
— NEJM (@NEJM) August 27, 2022
#ESCCongress | In patients within 6 months of a myocardial infarction, a polypill containing aspirin, ramipril, and atorvastatin resulted in a lower risk of major adverse cardiovascular events compared to usual care.
29 Aug, 2022 | 12:27h | UTCPolypill Strategy in Secondary Cardiovascular Prevention – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Polypill reduces cardiovascular events in heart attack patients compared to usual care – European Society of Cardiology
Commentaries:
Polypill Strategy Lowers Adverse CV Event Risk in Secondary Prevention – HCPLive
Related: M-A: Polypills with and without aspirin substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularization, and cardiovascular death in primary cardiovascular disease prevention. (several studies on the subject)
#ESCCongress – RCT | A large study with 46.611 individuals between 65 and 74 years of age found that a comprehensive cardiovascular screening program did not significantly reduce the incidence of death from any cause.
29 Aug, 2022 | 12:24h | UTCFive-Year Outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Cardiovascular screening may reduce risk of death and cardiovascular disease – European Society of Cardiology
Commentary on Twitter
DANCANVAS: In men age 65-74 years in Denmark, those randomized to invitation to comprehensive screening for subclinical CVD did not have signif reduced all-cause mortality at median 5.6 yrs of follow-up. #ESCCongress https://t.co/YZL87aTVHR pic.twitter.com/HfdiNuU9sK
— NEJM (@NEJM) August 27, 2022
[News release – not published yet] #ESCCongress – RCT | Allopurinol does not improve cardiovascular outcomes in ischemic heart disease patients.
29 Aug, 2022 | 12:15h | UTCCommentary:
ALL-HEART: Gout Drug Allopurinol No Help in CV Prevention – TCTMD
No improvement with allopurinol for patients with ischemic heart disease: ALL-HEART – Cardiology Now
Update on the management of diabetes in long-term care facilities.
26 Aug, 2022 | 13:23h | UTC
Randomized Crossover Trial | In patients with diabetic neuropathic pain, amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin were similarly effective.
25 Aug, 2022 | 12:14h | UTC
Study Commentary | Is the evidence strong for spinal cord stimulation for diabetic neuropathy? Not all experts agree.
25 Aug, 2022 | 11:52h | UTCOriginal Study: RCT: Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy
USPSTF Recommendation Statement | Statin use for the primary prevention of cardiovascular disease in adults.
24 Aug, 2022 | 14:21h | UTCEditorials:
Author Interview: USPSTF Recommendation: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults – JAMA
Patient Page: Statins for the Prevention of Cardiovascular Disease – JAMA
Commentary: Latest statins guidance keeps more conservative approach to preventing first stroke or heart attack – CNN
Non-nutritive sweeteners affect human microbiomes and can alter glycemic responses.
24 Aug, 2022 | 14:17h | UTCNews Release: Non-nutritive sweeteners affect human microbiomes and can alter glycemic responses – Cell Press
Original Study: Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance – Cell
Commentary on Twitter
The skinny on non-nutritive sweeteners (they are not inert) via a randomized trial & gut #microbiome assessment: impact is individualized and can impair glycemic responsehttps://t.co/B7CUPy7tMf @CellCellPress @SuezLab @EranElinav @segal_eran @WeizmannScience @Yot_Coh @Elinav_Lab pic.twitter.com/Jz7lUkWlNr
— Eric Topol (@EricTopol) August 19, 2022
Podcast | USPSTF Update: aspirin for primary prevention of cardiovascular disease.
24 Aug, 2022 | 14:05h | UTC#347 USPSTF Update: Aspirin for Primary Prevention of CVD – The Curbsiders
Related Guideline: USPSTF Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease.
Related Randomized Trials:
Randomized Trial: Aspirin for Primary Prevention of Cardiovascular Disease
Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes
Randomized Trial: Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
Related Meta-Analysis:
Meta-Analysis: Efficacy and Safety of Aspirin for Primary Prevention of Cardiovascular Events
Related Opinions:
Aspirin for Primary Prevention: Is This the End of the Road?
Evidence evolving on aspirin as prevention – ACP Internist
Guideline | Management of adults with diabetes on dialysis.
23 Aug, 2022 | 13:16h | UTCManagement of adults with diabetes on dialysis – Joint British Diabetes Societies for Inpatient Care (PDF)
News Release: Latest JBDS dialysis guideline published – Diabetes Times
RCT | Effectiveness of an intervention for reducing sitting time and improving health in office workers.
22 Aug, 2022 | 12:19h | UTCEditorial: The importance of sitting less and moving more – The BMJ
News Release: Standing desks alongside other measures cut office workers’ sitting time by an hour a day – BMJ Newsroom
Commentary: SMART Work and Life Intervention Reduces Sitting Time for Office Workers – HealthDay
Commentary on Twitter
Using a standing desk alongside a package of other measures to encourage office workers to sit less and move more, reduced sitting time by about an hour a day over one year, finds a trial published in @bmj_latest today https://t.co/uxaDWnp5WB
— The BMJ (@bmj_latest) August 18, 2022